Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00220493|
Recruitment Status : Unknown
Verified January 2007 by Sheba Medical Center.
Recruitment status was: Recruiting
First Posted : September 22, 2005
Last Update Posted : January 5, 2007
Growing awareness and accumulating data regarding the cognitive impairment and its progression in multiple sclerosis (MS) patients has received an important place in neurological research in the last decade.
|Condition or disease||Intervention/treatment||Phase|
|Relapsing Remitting Multiple Sclerosis Multiple Sclerosis, Chronic Progressive||Drug: Ritalin||Phase 1|
Growing awareness and accumulating data regarding the cognitive impairment and its progression in multiple sclerosis (MS) patients has received an important place in neurological research in the last decade. Cognitive impairments occur frequently (43 to 65%) in MS. Moreover, in up to 50% of patients in whom no cognitive disturbances are found on routine neurological examination, cognitive impairments can be elicited using sensitive and disease specific neuropsychological tests. Even in patients with short disease duration of less than two years, discrete impairment of cognitive function may be found in up to 60% on neuropsychological testing without impacting activities of daily living.
We have recently reported that cognitive impairment occurred in 53.7% of patients with probable MS (evaluated within a mean of one month of the onset of new neurological symptoms). Verbal abilities and attention span were most frequently affected (43.3 and 41.8% respectively). An additional study demonstrated that MS patients within the first 5 years of disease onset presented attentional dysfunction only when the cognitive load of the attention task was high and when controlled information processing was required. This high rate of attention impairment found in MS patients early in the disease process may have a significant impact on quality of life and activities of daily living as attention is one of the most fundamental cognitive functions essential for normal daily activities and a requisite step towards conscious perception. Consequently, we suggest investigating whether treatment with Ritalin (methylphenidate) has an effect on patients.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Clinical Study Protocol: Evaluation of the Efficiency of Ritalin in Multiple Sclerosis Patients|
|Study Start Date :||June 2003|
|Study Completion Date :||June 2005|
- Score on the Paced Auditory Serial Addition Test (PASAT) one hour after taking the drug/placebo
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00220493
|Contact: Anat Achiron, MD PhD||972-3-5303932||ACHIRON@POST.TAU.AC.IL|
|Contact: Nava Appleboim-Gavish, MAfirstname.lastname@example.org|
|Multiple Sclerosis Center||Recruiting|
|Ramat Gan, Israel, 52621|
|Principal Investigator: Anat Achiron, MD PhD|
|Principal Investigator:||Anat Achiron, MD PhD||Sackler School of Medicine|
|Principal Investigator:||Yirmiyahu Harel, MD||Sachler School of Medicine|
|Principal Investigator:||Nava Appleboim-Gavish, MA||Sheba Medical Center at Tel Hashomer Israel|